Prescription drug denials by private insurers in the U.S. rose from 18.3% to 22.9% from 2016 to 2023, with rejections up across many health plans, Sarah Kliff of The New York Times reports, citing data compiled for the journal by Komodo Health. Experts who have studied denials say the rising costs of new weight loss medications and the automation of the claims process with AI may have contributed to rising rejection rates. Publicly traded companies in the space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Trump Trade: U.S. slaps 30% tariff rate on EU, Mexico
- Fight brewing over Medicare drug negotiation program, Bloomberg Law reports
- Pressure continues to mount on health insurers as costs rise, WSJ says
- JPMorgan says too early to conclude other MCOs exposed to same risk as Centene
- Closing Bell Movers: Centene down 24% after pulling 2025 guidance